Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
Bradley A. McGregor(Harvard University), Toni K. Choueiri(Harvard University), Kathryn P. Gray(Dana-Farber Cancer Institute), Michelle S. Hirsch(Perinatal Institute), Ziad Bakouny(Dana-Farber Cancer Institute), Lillian Werner(Dana-Farber Cancer Institute), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Kerry L. Kilbridge(Dana-Farber Cancer Institute), Xiao X. Wei(Dana-Farber Cancer Institute), John A. Steinharter(Memorial Sloan Kettering Cancer Center), Sabina Signoretti(Brigham and Women's Hospital), Lauren C. Harshman(Dana-Farber Cancer Institute), Rana R. McKay(University of California San Diego), Abdallah Flaifel(Brigham and Women's Hospital), David A. Braun(Yale Cancer Center), Ulka N. Vaishampayan(University of Michigan), Atish D. Choudhury(Dana-Farber Cancer Institute), Ronan Flippot(Institut Gustave Roussy), Gordon J. Freeman(Dana-Farber Cancer Institute), David F. McDermott(Beth Israel Deaconess Medical Center)
Cited by 147
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k